サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514208

肝臓がん治療薬の世界市場

Liver Cancer Drugs

出版日
ページ情報
英文 277 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
肝臓がん治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 277 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝臓がん治療薬の世界市場は2030年までに93億米ドルに達する見込み

2023年に28億米ドルと推定される肝臓がん治療薬の世界市場は、2023～2030年の分析期間においてCAGR 18.4%で成長し、2030年には93億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的薬物療法は、CAGR 18.5%を記録し、分析期間終了時には51億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間のCAGRで16.2％と推定されます。

米国市場は推定7億6,380万米ドル、中国はCAGR24.4％で成長予測

米国の肝臓がん治療薬市場は、2023年に7億6,380万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR24.4%を牽引し、2030年までに市場規模23億米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.6%と15.7%と予測されています。欧州では、ドイツがCAGR約14.5％で成長すると予測されています。

肝臓がん治療薬-主要動向と促進要因

肝臓がん治療薬には、肝細胞がん（HCC）や肝臓の他の悪性腫瘍の治療を目的とした多様な治療オプションが含まれています。原発性肝がんの中で最も一般的な肝細胞がんは、B型肝炎やC型肝炎、非アルコール性脂肪性肝炎（NASH）、肝硬変などの慢性肝疾患に伴って発症することが多いです。肝臓の機能は複雑であり、体内の代謝プロセスにおいて重要な役割を担っているため、肝臓がんの治療は歴史的に困難な課題でした。手術や経動脈的化学塞栓療法（TACE）のような局所療法を含む従来の治療法は、全身治療の出現によって補完されてきました。ソラフェニブやレンバチニブなどの標的療法は、腫瘍増殖や血管新生に関与する特定の経路を阻害することで、進行肝がんの管理に不可欠です。これらの薬剤は生存に大きな利益をもたらしているが、患者のQOLに影響を与える副作用を伴うことが多いです。

近年、免疫療法が肝がん治療の画期的なアプローチとして浮上してきました。ペムブロリズマブやニボルマブなどの免疫チェックポイント阻害剤は、がん細胞に対する身体の免疫反応を増強することで有望視されています。これらの治療薬は、免疫系の活動を阻害するタンパク質をブロックすることにより、T細胞ががん細胞をより効果的に攻撃できるようにします。さらに、免疫療法を標的治療やその他の治療法と統合する併用療法も臨床試験で積極的に検討されています。例えば、アテゾリズマブとベバシズマブの併用療法は、従来の単剤療法と比較して治療成績の改善を示しています。これらの進歩は、より個別化された効果的な治療レジメンへのシフトを強調するものであり、生存期間の延長だけでなく、肝がん患者の全体的なQOLの向上を目指すものです。

肝臓がん治療薬市場の成長は、いくつかの要因によってもたらされます。第一に、特に肝炎感染やNASHの有病率が高い地域で肝がんの罹患率が上昇し、効果的な治療に対する需要が高まっています。第二に、医薬品開発とゲノム研究における技術的進歩が、新規治療標的の発見とより効果的な薬剤の開発を促進しています。第三に、免疫療法や標的治療の成功が研究開発への多額の投資を呼び込み、競争的で革新的な市場環境が醸成されています。さらに、規制当局が画期的な治療薬に対して迅速な承認を行っているため、患者への新たな治療法の提供が迅速化されています。相乗効果と治療成績の改善をもたらす併用療法の採用が増加していることも、市場の成長をさらに後押ししています。さらに、早期診断や高度な治療オプションの利点に関するヘルスケアプロバイダーや患者の意識の高まりが、新薬の採用率の上昇につながっています。最後に、新興国におけるヘルスケアインフラの拡充と先進医療へのアクセスが市場成長の新たな機会を生み出し、革新的な肝がん治療がより多くの患者に行き渡ることを確実にしています。これらの要因が総合的に、肝臓がん治療薬市場の堅調な拡大とダイナミックな進化に寄与しています。

調査対象企業の例（全52件）

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck & Co., Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6297

Global Liver Cancer Drugs Market to Reach US$9.3 Billion by 2030

The global market for Liver Cancer Drugs estimated at US$2.8 Billion in the year 2023, is expected to reach US$9.3 Billion by 2030, growing at a CAGR of 18.4% over the analysis period 2023-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 16.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$763.8 Million While China is Forecast to Grow at 24.4% CAGR

The Liver Cancer Drugs market in the U.S. is estimated at US$763.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 24.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Liver Cancer Drugs - Key Trends and Drivers

Liver cancer drugs encompass a diverse range of therapeutic options aimed at treating hepatocellular carcinoma (HCC) and other malignancies of the liver. HCC, the most common type of primary liver cancer, often develops in the context of chronic liver diseases such as hepatitis B and C infections, non-alcoholic steatohepatitis (NASH), and cirrhosis. The treatment landscape for liver cancer has historically been challenging due to the complexity of the liver’s function and its vital role in the body’s metabolic processes. Traditional approaches, including surgery and localized therapies like transarterial chemoembolization (TACE), have been complemented by the advent of systemic treatments. Targeted therapies, such as sorafenib and lenvatinib, have been integral in managing advanced liver cancer by inhibiting specific pathways involved in tumor growth and angiogenesis. These drugs have provided significant survival benefits, although they are often associated with considerable side effects that can impact patients' quality of life.

In recent years, immunotherapy has emerged as a groundbreaking approach in the treatment of liver cancer. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown promise in enhancing the body’s immune response against cancer cells. These therapies work by blocking proteins that inhibit immune system activity, thus allowing T-cells to attack cancer cells more effectively. Additionally, combination therapies that integrate immunotherapies with targeted treatments or other modalities are being actively explored in clinical trials. The combination of atezolizumab and bevacizumab, for example, has demonstrated improved outcomes compared to traditional monotherapies. These advancements underscore a shift towards more personalized and effective treatment regimens, which not only aim to extend survival but also improve the overall quality of life for patients with liver cancer.

The growth in the liver cancer drugs market is driven by several factors. Firstly, the rising incidence of liver cancer, particularly in regions with high prevalence of hepatitis infections and NASH, has increased the demand for effective treatments. Secondly, technological advancements in drug development and genomic research have facilitated the discovery of novel therapeutic targets and the development of more effective drugs. Thirdly, the success of immunotherapies and targeted therapies has attracted significant investment in research and development, fostering a competitive and innovative market environment. Additionally regulatory agencies are providing accelerated approvals for breakthrough therapies, which helps expedite the availability of new treatments to patients. The increasing adoption of combination therapies, which offer synergistic effects and improved outcomes, further drives market growth. Furthermore, heightened awareness among healthcare providers and patients about the benefits of early diagnosis and advanced treatment options has led to a higher adoption rate of new drugs. Lastly, the expansion of healthcare infrastructure and access to advanced medical treatments in emerging economies is creating new opportunities for market growth, ensuring that innovative liver cancer therapies reach a broader patient population. These factors collectively contribute to the robust expansion and dynamic evolution of the liver cancer drugs market.

Select Competitors (Total 52 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Liver Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Liver Cancer Expands Addressable Market Opportunity
    • Advances in Immunotherapy Throws the Spotlight on Novel Treatment Approaches
    • Rising Geriatric Population Strengthens Business Case for Liver Cancer Drugs
    • Enhanced Drug Delivery Systems Drives Adoption of Liver Cancer Drugs
    • Increasing Awareness and Early Diagnosis Spurs Growth in Treatment Demand
    • Technological Innovations in Drug Development Generates New Market Opportunities
    • Robust Pipeline of Liver Cancer Drugs Boost Future Market Growth
    • Rising Healthcare Expenditure Sustains Growth of Liver Cancer Treatment Market
    • Combination Therapies Expand Treatment Options and Market Potential
    • Personalized Treatment Plans Enhance Treatment Efficacy and Market Demand
    • Improved Patient Outcomes Generates Confidence in Liver Cancer Drug Market
    • Increasing Use of Biomarkers and Genomics Expands Addressable Market Opportunity
    • Market Penetration in Emerging Economies Fuel Growth Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • JAPAN
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • CHINA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • EUROPE
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • FRANCE
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • GERMANY
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • INDIA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Liver Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Liver Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • AFRICA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION